Gastrointestinal cancer: A step closer to combating acquired resistance in CRC

Nature Reviews Clinical Oncology

Volumn 9, Issue 8, 2012, Pages 428-

  Hutchinson, Lisa ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; DNA FRAGMENT; K RAS PROTEIN; PANITUMUMAB; VASCULOTROPIN;

BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER RESISTANCE; COLORECTAL CANCER; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HUMAN; METASTASIS POTENTIAL; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MUTATIONAL ANALYSIS; NOTE; ONCOGENE K RAS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; TUMOR BIOPSY;

EID: 84864472837     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2012.114     Document Type: Note

References (2)

1. Misale, S. et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature doi:10.1038/nature11156
2. Diaz, L. A. et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature doi:10.1038/nature11219